Neuroendocrine carcinoma

NEC has poorly differentiated small-cell or large-cell morphology. Pathologists integrate the microscopic pattern, neuroendocrine markers and proliferation; a high Ki-67 percentage alone is insufficient. A small or damaged biopsy may need specialist review or additional tissue before a major treatment decision.

The prospective NORDIC NEC 2 study, published in 2025, confirmed substantial differences between digestive NEC and well-differentiated G3 NET after central pathology review. This supports retaining the full diagnosis in records rather than shortening everything to “high-grade neuroendocrine cancer.” Its population averages do not predict an individual patient’s survival.

For well-differentiated disease, the NET guide explains the separate pathway.

A neuroendocrine cancer in the liver can be a metastasis from elsewhere. Imaging, endoscopy when appropriate and pathology help establish origin. Mixed neuroendocrine–non-neuroendocrine neoplasms (MiNENs) contain different components; a biopsy may sample only one. Treatment planning considers the aggressive component and the tissue present in metastatic sites, not only whichever component is largest in the original tumor.

Lung small-cell cancer and Merkel cell carcinoma have dedicated guides.

Contrast CT or MRI establishes local extent, nodes and distant disease. FDG PET can clarify selected high-grade disease; receptor imaging is not a substitute. Brain imaging is guided by primary site, symptoms and clinical risk. Preventive brain radiation used in some small-cell lung settings is not automatically appropriate for digestive NEC.

Potentially curative treatment may combine surgery, chemotherapy and radiotherapy according to the organ and resectability. Surgery alone can leave a substantial risk of distant relapse; for some sites, definitive chemoradiation avoids a highly morbid operation. Review the sequence with a multidisciplinary team before surgery, including whether chemotherapy should come first and how margins or involved nodes affect the plan.

For many advanced digestive NECs, etoposide with cisplatin or carboplatin is a common starting approach. Cisplatin–irinotecan is another option in appropriate settings. TOPIC-NEC did not show overall-survival superiority of cisplatin–irinotecan over cisplatin–etoposide. Its older classification and selected trial population matter when applying the findings.

The choice also depends on kidney function, hearing, neuropathy, blood counts, diarrhea risk and fitness. Tumor shrinkage can occur, but early reassessment is important because primary resistance is possible. Fever during chemotherapy, inability to maintain fluids or new severe weakness warrants prompt contact with the treatment team.

After progression, FOLFIRI is a reasonable option for selected digestive NECs. In PRODIGE 41-BEVANEC, adding bevacizumab did not appear to improve survival benefit. The next choice depends on prior response, how soon disease returned, organ function and patient priorities; there is no universally best second-line regimen.

NET-02 evaluated liposomal irinotecan with fluorouracil/folinic acid and docetaxel in previously treated extrapulmonary NEC. The liposomal regimen met its predefined six-month progression-free survival endpoint, but overall survival was similar between groups. This small phase 2 selection study should not be presented as a definitive survival-winning comparison.

Some patients respond to dual checkpoint blockade, but benefit is not universal. The 2026 NIPINEC trial enrolled platinum-pretreated digestive NEC and lung large-cell NEC. With nivolumab–ipilimumab, the eight-week response rate was 14%; responses at any time were more frequent, but median progression-free and overall survival were limited and similar between study arms. This supports a selective discussion, not a promise that dual immunotherapy is better for everyone.

The small DART high-grade cohort showed durable responses in a subset. NICE-NEC tested first-line nivolumab plus platinum chemotherapy in a mixed high-grade population but did not meet its primary survival endpoint. SWOG S2012 is testing whether adding atezolizumab helps extrapulmonary small-cell NEC. These studies should not be merged into an established universal immunotherapy standard.

Molecular testing may identify a treatment-relevant alteration or a biomarker such as MSI-H/dMMR. Pembrolizumab has a US tumor-agnostic indication for qualifying unresectable or metastatic MSI-H/dMMR solid tumors after prior treatment when satisfactory alternatives are lacking. Eligibility follows the full label and clinical context; PD-L1 staining alone does not establish the same indication.

DLL3-directed T-cell engagers are an active research direction. Tarlatamab has an FDA indication for previously treated extensive-stage small-cell lung cancer; that does not cover all extrapulmonary NECs. Trials are assessing wider high-grade neuroendocrine populations, sometimes with radiation. Ask about histology, DLL3 testing, prior-treatment requirements and monitoring for cytokine-release and neurologic effects.

Agree on the first response-assessment date and the symptoms that should trigger earlier review. Follow-up tracks both cancer and treatment burden, including nutrition, pain, blood counts and daily function. Supportive care can run alongside anticancer treatment, especially when another regimen is unlikely to deliver meaningful control.

Bring the original pathology slides or blocks where available, differentiation and Ki-67 results, site-specific imaging, any molecular report, and dated treatment/response records. Ask whether the diagnosis is unequivocal NEC, whether mixed components matter, and whether a trial is feasible before starting another line.